- Gubra and Bayer started the collaboration in 2021
- Gubra will actively (alone or with a new partner) continue further development of the cardio-renal metabolic peptide programme
- Gubra sees great potential for this drug programme within the area of healthy weight loss
Gubra today announced the termination of its cardio-renal peptide programme collaboration with Bayer AG. Bayer will return the asset following a portfolio review.
“We have matured the programme in a very short timeframe with a successful collaboration with Bayer, which is a testimony to the strength of our streaMLine peptide drug discovery engine,” said Henrik Blou, CEO of Gubra A/S. “We see great potential for developing the programme within ‘healthy weight loss,’ one of the other core areas at Gubra. With this recent news, we are now evaluating whether to proceed into further development ourselves or with a partner, but the programme definitely has a strong place in our pipeline.”
The peptide programme was licensed to Bayer in 2021 and Gubra was eligible to receive milestone payments and royalties on global sales which will no longer be the case as the programme is handed back. Gubra will communicate the potential of further development of this metabolic programme at a later stage when the different development and partnership options have been thoroughly evaluated.